← FDA DRUG APPROVALS

FDA ANDA · ANDA070615

PROPOXYPHENE NAPSYLATE AND ACETAMINOPHEN

Sponsor: MUTUAL PHARM

APPLICATION
ANDA070615
TYPE
ANDA
ORIGINAL APPROVAL
1986-03-21
LATEST ACTION
1998-12-01
ROUTE
ORAL
DOSAGE FORM
TABLET
MARKETING STATUS
Discontinued

Products

PROPOXYPHENE NAPSYLATE AND ACETAMINOPHENDiscontinued
ACETAMINOPHEN 650MG, PROPOXYPHENE NAPSYLATE 100MG · TABLET · ORAL

Approval history

1998-12-01Manufacturing (CMC) · Supplement 14AP
1994-12-23Manufacturing (CMC) · Supplement 13AP
1992-04-03Manufacturing (CMC) · Supplement 12AP
1992-04-03Manufacturing (CMC) · Supplement 10AP
1988-09-16Manufacturing (CMC) · Supplement 9AP
1987-08-19Manufacturing (CMC) · Supplement 6AP
1987-04-01Manufacturing (CMC) · Supplement 4AP
1986-03-21OriginalAP
VIEW ON DRUGS@FDA ↗

Related on SPEQ

Pharma industry →GMP discipline →FDA drug shortages →FDA enforcement & recalls →

Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →